Pharmaceutical News

RSS

Mylan, Shionogi and CIMA Labs to resolve generic Orapred ODT patent litigation

Mylan Inc. today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg.

10 Oct 2012

Researchers discover mechanism by which magnesium reduces cytokine production

Magnesium sulfate is given to many pregnant women to treat preterm labor and preeclampsia and was recently shown to prevent cerebral palsy; however little is known about how it works. Researchers at Case Western Reserve University School of Medicine recently discovered the mechanism by which magnesium reduces the production of cytokines.

10 Oct 2012

Anesthetic-loaded liposomes can delay onset of neuropathic pain

Using tiny spheres filled with an anesthetic derived from a shellfish toxin, researchers at Boston Children's Hospital and the Massachusetts Institute of Technology have developed a way to delay the rise of neuropathic pain, a chronic form of pain that arises from flawed signals transmitted by damaged nerves.

10 Oct 2012

QRxPharma, Paladin execute licensing agreement for MOXDUO

QRxPharma Limited announced today execution of a licensing agreement with Paladin Labs Inc. for the Canadian commercialisation rights to MOXDUO, a patented, immediate release formulation of morphine and oxycodone.

10 Oct 2012

AFPE, AAPS enter new strategic alliance to advance pharmaceutical science education

The American Association of Pharmaceutical Scientists (AAPS) and the American Foundation for Pharmaceutical Education (AFPE) have entered into an exciting new strategic alliance to advance support for pharmaceutical science education.

10 Oct 2012

Aspirin associated with reduced risk of serious ovarian cancer

New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serious ovarian cancer—an aggressive carcinoma affecting the surface of the ovary.

10 Oct 2012

Pieris achieves milestone in Anticalin discovery and development collaboration with Daiichi Sankyo

Pieris AG announced today the achievement of the first financial milestone in its discovery and development collaboration with Daiichi Sankyo Company Limited.

9 Oct 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

Financial Times examines use of financial transaction taxes to raise development funds

The Financial Times examines the creation of UNITAID, an innovative financing mechanism and international drug purchasing facility, and how Philippe Douste-Blazy, chair of the UNITAID Executive Board and France's former foreign minister who helped create the organization, is looking to move beyond drug financing to raise money through "microdonations" for development programs.

9 Oct 2012

Scripps scientists to study several compounds with potential to improve QOL for ALS patients

A team led by scientists at The Scripps Research Institute has been awarded $2.1 million by the Department of Defense Congressionally Directed Medical Research Programs to study several compounds with the potential to greatly improve the quality of life for those with amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease.

9 Oct 2012

Uniquest, Aquavit Life Sciences announce MOU to form Alliance Partnership

Aquavit Life Sciences, Inc., a wholly owned subsidiary of Aquavit Pharmaceuticals, Inc., announces together with Uniquest Corporation (KOSPI: 077500) a Memorandum Of Understanding to form an Alliance Partnership for the development, registration and manufacturing of Aquavit Pharmaceuticals' PITO-001.

9 Oct 2012

Maternal depression treated by SRIs can change the timing of language development in babies

Maternal depression and a common class of antidepressants can alter a crucial period of language development in babies, according to a new study by researchers at the University of British Columbia, Harvard University and the Child & Family Research Institute (CFRI) at BC Children's Hospital.

9 Oct 2012

Myths about the influenza vaccine

With cold and flu season upon us, many companies have geared up for what is predicted to be a busy flu season producing 150 million doses of the influenza vaccine, up 17 million from last year.

9 Oct 2012

FDA task force to examine solutions to improve, speed antibiotic research

"One of the most urgent global public health problems is the increasing capability of bacteria to resist antibiotic drugs," a Washington Post editorial states.

8 Oct 2012

New neuroprotective agent for stroke patients potentially found

Scientists have shown that a drug called NA-1 results in fewer brain lesions in patients who have undergone surgery to repair a brain aneurysm, compared to placebo, and appears to be safe to use, according to an Article published Online First in The Lancet Neurology.

8 Oct 2012

Loose oversight may be to blame in meningitis outbreak

The rising toll - 7 dead, 57 ill and thousands potentially exposed - has cast a harsh light on the loose regulations that legal experts say allowed a company to sell 17,676 vials of an unsafe drug to pain clinics in 23 states.

8 Oct 2012

USPTO grants five-year extension to Spectrum's FOLOTYN patent

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN (pralatrexate injection).

8 Oct 2012

Almac signs collaboration agreement with DSM in the field of biocatalysis

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced today that it has signed a collaboration agreement with the Almac Group Ltd. (UK) in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry.

8 Oct 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.

8 Oct 2012